Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2020 Jan;82(1):47-56.
doi: 10.1097/PSY.0000000000000759.

Placebo Effects in the Neuroendocrine System: Conditioning of the Oxytocin Responses

Affiliations
Controlled Clinical Trial

Placebo Effects in the Neuroendocrine System: Conditioning of the Oxytocin Responses

Aleksandrina Skvortsova et al. Psychosom Med. 2020 Jan.

Abstract

Objective: There is evidence that placebo effects may influence hormone secretion. However, few studies have examined placebo effects in the endocrine system, including oxytocin placebo effects. We studied whether it is possible to trigger oxytocin placebo effects using a classical conditioning paradigm.

Methods: Ninety-nine women were assigned to a conditioned, control, or drug control group. In the two-phase conditioning paradigm, participants in the conditioned and drug control groups received an oxytocin nasal spray combined with a distinctive smell (conditioned stimulus [CS]) for three acquisition days, whereas the control group received placebo spray. Subsequently, the conditioned and control groups received placebo spray with the CS and the drug control group received oxytocin spray for three evocation days. Salivary oxytocin was measured several times during each day. Pain sensitivity and facial evaluation tests previously used in oxytocin research were also administered.

Results: On evocation day 1, in the conditioned group, oxytocin significantly increased from baseline to 5 minutes after CS (B[slope] = 19.55, SE = 5.88, p < .001) and remained increased from 5 to 20 (B = -10.42, SE = 5.81, p = .071) and 50 minutes (B = -0.70, SE = 3.37, p = .84). On evocation day 2, a trend for increase in oxytocin was found at 5 minutes (B = 15.22, SE = 8.14, p = .062). No placebo effect was found on evocation day 3 (B = 3.57, SE = 3.26, p = .28). Neither exogenous nor conditioned oxytocin affected pain or facial tasks.

Conclusions: Results indicate that oxytocin release can be conditioned and that this response extinguishes over time. Triggering hormonal release by placebo manipulation offers various clinical possibilities, such as enhancing effects of pharmacological treatments or reducing dosages of medications.

Trial registration: The study was registered as a clinical trial on www.trialregister.nl (number NTR5596).

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Study design.
FIGURE 2
FIGURE 2
Timeline of the experimental days. US = unconditioned stimulus; CS = conditioned stimulus.
FIGURE 3
FIGURE 3
Salivary oxytocin levels (in picograms per milliliter) on evocation days 1 (A), 2 (B), and 3 (C) separately for each group (n = 99). Error bars indicate SEs. Color image is available only in the online version (www.psychosomaticmedicine.org).

Similar articles

Cited by

References

    1. Forsberg JT, Martinussen M, Flaten MA. The placebo analgesic effect in healthy individuals and patients: a meta-analysis. Psychosom Med 2017;79:388–94. - PubMed
    1. Shaibani A, Frisaldi E, Benedetti F. Placebo response in pain, fatigue, and performance: possible implications for neuromuscular disorders. Muscle Nerve 2017;56:358–67. - PubMed
    1. Pollo A, Carlino E, Benedetti F. Placebo mechanisms across different conditions: from the clinical setting to physical performance. Philos Trans R Soc Lond Biol 2011;366:1790–8. - PMC - PubMed
    1. Benedetti F, Amanzio M, Thoen W. Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology (Berl) 2011;213:791–7. - PubMed
    1. Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med 2011;17:1228–30. - PubMed

Publication types

Associated data